Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The expansion includes a larger technical and service team and increased local procurement
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
Subscribe To Our Newsletter & Stay Updated